Annotation Detail

Information
Associated Genes
HMOX1
Associated Variants
HMOX1 EXPRESSION
HMOX1 EXPRESSION
Associated Disease
renal cell carcinoma
Source Database
CIViC Evidence
Description
In 66 patients with advanced renal cell carcinoma, high expression of heme oxygenase-1 (HO-1) was associated with poor overall response rate (2.6% versus 53.6%, P<0.01), clinical benefit rate (47.4% versus 92.9%, P<0.01), shorter progression-free survival (4.4 versus 42 months, P=0.022) and poor overall survival (χ (2)=4.775, P=0.029) in patients receiving sorafenib or sunitinib.
Variant Origin
N/A
Variant Origin
N/A
Evidence URL
https://civic.genome.wustl.edu/links/evidence_items/829
Gene URL
https://civic.genome.wustl.edu/links/genes/2657
Variant URL
https://civic.genome.wustl.edu/links/variants/344
Rating
3
Evidence Type
Predictive
Disease
Renal Cell Carcinoma
Evidence Direction
Supports
Drug
Sunitinib,Sorafenib
Evidence Level
B
Clinical Significance
Resistance
Pubmed
26309414
Drugs
Drug NameSensitivitySupported
SorafenibResitance or Non-Reponsetrue
SunitinibResitance or Non-Reponsetrue